Apogee Therapeutics reports FY results

Apogee Therapeutics reported a significant increase in cash and marketable securities, totaling $731.1 million at the end of fiscal year 2024, up from $395.5 million in 2023.

The company forecasts that its financial resources will be sufficient to cover operating expenses until at least the first quarter of 2028 based on current operational strategies.

Despite the positive financial position, Apogee experienced a net loss of $182.1 million in 2024, which is a worsened financial outcome compared to a net loss of $84.0 million in 2023.

Financial Overview and Outlook for Apogee Therapeutics

Recommendation Rating: Positive

Apogee Therapeutics (NASDAQ: APGE) has released its financial results for the fiscal year ending December 31, 2024. As of this date, the company reported cash, cash equivalents, and marketable securities totaling $731.1 million, a substantial increase from $395.5 million recorded on December 31, 2023.

Looking ahead, Apogee anticipates that its current financial resources will adequately cover operating expenses through the first quarter of 2028, based on its existing operational strategies.

However, the company faced a net loss of $182.1 million for the year ending December 31, 2024. This marks an increase in losses compared to the previous year's net loss of $84.0 million for the year ending December 31, 2023.